Myriad Genetics, Inc. (MYGN)
- Previous Close
18.49 - Open
18.51 - Bid 18.55 x 100
- Ask 18.61 x 100
- Day's Range
18.51 - 19.00 - 52 Week Range
13.82 - 24.21 - Volume
493,803 - Avg. Volume
615,119 - Market Cap (intraday)
1.683B - Beta (5Y Monthly) 1.98
- PE Ratio (TTM)
-- - EPS (TTM)
-3.18 - Earnings Date May 1, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
23.91
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and pharmacogenomics. It also provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, and Onsite Women's Health. Myriad Genetics, Inc. was incorporated in 1992 and is headquartered in Salt Lake City, Utah.
www.myriad.com2,700
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: MYGN
Performance Overview: MYGN
Trailing total returns as of 4/23/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MYGN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MYGN
Valuation Measures
Market Cap
1.67B
Enterprise Value
1.68B
Trailing P/E
--
Forward P/E
2.00k
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.03
Price/Book (mrq)
2.14
Enterprise Value/Revenue
2.24
Enterprise Value/EBITDA
-8.53
Financial Highlights
Profitability and Income Statement
Profit Margin
-34.96%
Return on Assets (ttm)
-7.40%
Return on Equity (ttm)
-31.55%
Revenue (ttm)
753.2M
Net Income Avi to Common (ttm)
-263.3M
Diluted EPS (ttm)
-3.18
Balance Sheet and Cash Flow
Total Cash (mrq)
140.9M
Total Debt/Equity (mrq)
19.42%
Levered Free Cash Flow (ttm)
-61.42M
Research Analysis: MYGN
Company Insights: MYGN
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: MYGN
MYGN: Lowering target price to $20.00
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $20.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetMYGN: Raising target price to $22.00
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $22.000000; an Industry Subrating of Low; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetMYGN: Raising target price to $21.00
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $21.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice TargetMYGN: Rating increased to a HOLD
MYRIAD GENETICS INC has an Investment Rating of HOLD; a target price of $19.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Medium.
RatingPrice Target